Argosy Healthcare Partners Completes Recapitalization of Command Medical Products

Argosy Healthcare Partners Completes Recapitalization of Command Medical Products

Argosy Healthcare Partners (AHP) has announced a recapitalization and partnership with Command Medical Products to support its next stage of growth. This deal was facilitated and managed by MedWorld Advisors, a leading middle-market M&A advisory firm. Financial terms of the deal were not disclosed.  Command Medical Products provides contract manufacturing services for the production of single-use disposable medical devices to global medical device original equipment manufacturers and life sciences customers. Headquartered in Ormond Beach, Florida and founded in 1987, the company provides customized clean room manufacturing of single-use medical devices leveraging key technologies,... Read More »
Argosy Healthcare Partners Completes Recapitalization of Command Medical Products

Novo Holdings Acquires Catalent for $16.5 Billion

Novo Holdings A/S announced that it will acquire Catalent, Inc. in an all-cash transaction that values Catalent at $16.5 billion on an enterprise value basis. The purchase price represents a premium of 16.5% to the closing price of Catalent’s common stock as of February 2, 2024, the last trading day prior to the announcement, and a 47.5% premium to the 60-day volume-weighted average price as of February 2, 2024.  Catalent is a contract development and manufacturing organization (CDMO) partner for personalized medicines, blockbuster drugs and consumer health brand extensions. The company was formed in April 2007 when affiliates of the Blackstone Group acquired the core of the... Read More »
Arlington Capital Partners Announces Majority Investment in Afton Scientific

Arlington Capital Partners Announces Majority Investment in Afton Scientific

Arlington Capital Partners has announced a majority investment in Afton Scientific, a contract, development and manufacturing organization (CDMO) dedicated to sterile manufacturing of injectable pharmaceuticals. According to data captured in the LevinPro HC database, this acquisition marks the third CDMO transaction of the year. There were 21 CDMO transactions announced during 2023, and 39 during 2022. Based in Charlottesville, Virginia, Afton Scientific specializes in sterile injectable drug manufacturing as well as providing pre-sterilized vials and kits. The company performs aseptic fill-finish for products ranging from pre-clinical through commercial-scale manufacturing across various... Read More »
Arlington Capital Partners Announces Majority Investment in Afton Scientific

Ajinomoto Acquires Forge Biologics for $620 Million

Ajinomoto Co., Inc. and Forge Biologics announced on November 13 that they have entered into a definitive agreement by which Ajinomoto will acquire Forge Biologics in an all-cash deal for $620 million.  Forge Biologics is a viral vector and plasmid contract development and manufacturing organization (CDMO) and clinical-stage therapeutics company, enabling access to potentially life-changing gene therapies by bringing them from concept to reality. All development and manufacturing is done at the Hearth, Forge Biologics’ 200,000 square-foot custom-designed cGMP facility in Columbus, Ohio, where the CDMO has more than 300 employees.  Ajinomoto Co. is a global manufacturer of... Read More »
Argosy Healthcare Partners Completes Recapitalization of Command Medical Products

SK Pharmteco Acquires Controlling Interest in Center for Breakthrough Medicines

SK Pharmteco, a division of South Korean conglomerate SK Inc., has acquired a controlling interest in the Center for Breakthrough Medicines.  The Center for Breakthrough Medicines is a King of Prussia, Pennsylvania-based contract development and manufacturing organization (CDMO) specializing in cell and gene therapy.  SK Pharmteco is based in Rancho Cordova, California. The company specializes in the production of active pharmaceutical ingredients, advanced intermediates and cell and gene therapy for the pharmaceutical industry.  SK Inc., the investment arm of SK Group in Seoul, previously invested $350 million in the Center for Breakthrough Medicines in December 2021. The... Read More »
Healthcare Subsectors Drive Double-Digit M&A Decline in 2023

Healthcare Subsectors Drive Double-Digit M&A Decline in 2023

There is no shortage of subsectors contributing to the overall double-digit percentage decline in healthcare M&A activity in 2023. According to the LevinPro HC database, there have been 1,299 healthcare M&A deals this year through July 31. This represents an 12% drop compared with the 1,481 transactions recorded during the same period in 2022. The 2023 total represents a 5% increase from the 1,240 deals posted in 2021 through July 31. Some of the subsectors that have contributed to the M&A activity decline this year include Contract Development Manufacturing Organizations (CDMO), healthcare staffing firms, infusion services companies, primary & value-based care... Read More »